A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial. - Iwuji, Collins C.; Churchill, Duncan; Bremner, Stephen; Perry, Nicky; To, Ye; Lambert, Debbie; Bruce, Chloe; Waters, Laura; Orkin, Chloe; Geretti, Anna Maria (BMC Infectious Diseases, 2020)